Biotech, where they could efficiently leverage Spain’s world-leading position in altruistically donation of tissue and organ samples for research, with the first technology worldwide enabling scale research in patient samples.

Vivia has developed PharmaFlow PM, a precision medicine test for the treatment of Hematological Malignances like Leukemia and Multiple Myeloma, that seeks to identify the best treatment option for each individual patient.

Vivia has also pioneered worldwide the development of “native environment” assays in whole patient samples across several indications and multiple mechanisms of action, capable of delivering truly translational pharmacological data that correlates with patient treatment outcome.

With these assets, Vivia has successfully engaged in partnering with pharmaceutical and biotechnology companies worldwide to provide unique precision medicine capabilities for patient-centric drug development and biomarker discovery.

Vivia’s team is made of highly qualified professionals, dedicated to improve the life expectancy and quality of life of cancer patients.